BIIB
Price
$257.01
Change
-$0.82 (-0.32%)
Updated
Sep 29, 6:59 PM EST
23 days until earnings call
LLY
Price
$536.97
Change
-$7.43 (-1.36%)
Updated
Sep 29, 6:59 PM EST
33 days until earnings call

BIIB vs LLY ᐉ Comparison: Which is Better to Invest?

Header iconBIIB vs LLY Comparison
Open Charts BIIB vs LLYBanner chart's image
Biogen
Price$257.01
Change-$0.82 (-0.32%)
Volume$485.24K
CapitalizationN/A
Eli Lilly & Co
Price$536.97
Change-$7.43 (-1.36%)
Volume$839.8K
CapitalizationN/A
View a ticker or compare two or three
BIIB vs LLY Comparison Chart

Loading...

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
VS
BIIB vs. LLY commentary
Oct 01, 2023

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIIB is a StrongSell and LLY is a StrongSell.

COMPARISON
Comparison
Oct 01, 2023
Stock price -- (BIIB: $257.06 vs. LLY: $537.13)
Brand notoriety: BIIB and LLY are both notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: BIIB: 78% vs. LLY: 100%
Market capitalization -- BIIB: $37.34B vs. LLY: $516.84B
BIIB [@Pharmaceuticals: Major] is valued at $37.34B. LLY’s [@Pharmaceuticals: Major] market capitalization is $516.84B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $516.84B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $79.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIIB’s FA Score shows that 0 FA rating(s) are green whileLLY’s FA Score has 3 green FA rating(s).

  • BIIB’s FA Score: 0 green, 5 red.
  • LLY’s FA Score: 3 green, 2 red.
According to our system of comparison, LLY is a better buy in the long-term than BIIB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LLY’s TA Score shows that 3 TA indicator(s) are bullish.

  • LLY’s TA Score: 3 bullish, 5 bearish.

Price Growth

BIIB (@Pharmaceuticals: Major) experienced а -0.24% price change this week, while LLY (@Pharmaceuticals: Major) price change was -2.44% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.89%. For the same industry, the average monthly price growth was -4.31%, and the average quarterly price growth was -3.13%.

Reported Earning Dates

BIIB is expected to report earnings on Oct 24, 2023.

LLY is expected to report earnings on Nov 02, 2023.

Industries' Descriptions

@Pharmaceuticals: Major (-0.89% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
A.I.dvisor published
a Summary for BIIB with price predictions.
OPEN
A.I.dvisor published
a Summary for LLY with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
LLY($517B) has a higher market cap than BIIB($37.3B). LLY has higher P/E ratio than BIIB: LLY (75.76) vs BIIB (14.06). LLY YTD gains are higher at: 47.996 vs. BIIB (-7.172). LLY has higher annual earnings (EBITDA): 9.14B vs. BIIB (3.82B). BIIB has more cash in the bank: 6.08B vs. LLY (2.83B). BIIB has less debt than LLY: BIIB (6.59B) vs LLY (18.8B). LLY has higher revenues than BIIB: LLY (29.5B) vs BIIB (9.97B).
BIIBLLYBIIB / LLY
Capitalization37.3B517B7%
EBITDA3.82B9.14B42%
Gain YTD-7.17247.996-15%
P/E Ratio14.0675.7619%
Revenue9.97B29.5B34%
Total Cash6.08B2.83B215%
Total Debt6.59B18.8B35%
FUNDAMENTALS RATINGS
BIIB vs LLY: Fundamental Ratings
BIIB
LLY
OUTLOOK RATING
1..100
5278
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
64
Fair valued
PROFIT vs RISK RATING
1..100
1001
SMR RATING
1..100
4717
PRICE GROWTH RATING
1..100
6037
P/E GROWTH RATING
1..100
8226
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LLY's Valuation (64) in the Pharmaceuticals Major industry is in the same range as BIIB (93) in the Biotechnology industry. This means that LLY’s stock grew similarly to BIIB’s over the last 12 months.

LLY's Profit vs Risk Rating (1) in the Pharmaceuticals Major industry is significantly better than the same rating for BIIB (100) in the Biotechnology industry. This means that LLY’s stock grew significantly faster than BIIB’s over the last 12 months.

LLY's SMR Rating (17) in the Pharmaceuticals Major industry is in the same range as BIIB (47) in the Biotechnology industry. This means that LLY’s stock grew similarly to BIIB’s over the last 12 months.

LLY's Price Growth Rating (37) in the Pharmaceuticals Major industry is in the same range as BIIB (60) in the Biotechnology industry. This means that LLY’s stock grew similarly to BIIB’s over the last 12 months.

LLY's P/E Growth Rating (26) in the Pharmaceuticals Major industry is somewhat better than the same rating for BIIB (82) in the Biotechnology industry. This means that LLY’s stock grew somewhat faster than BIIB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
LLY
RSI
ODDS (%)
Bearish Trend 2 days ago
56%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
68%
Momentum
ODDS (%)
Bearish Trend 2 days ago
55%
MACD
ODDS (%)
Bearish Trend 2 days ago
45%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
50%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
50%
Advances
ODDS (%)
Bullish Trend 6 days ago
67%
Declines
ODDS (%)
Bearish Trend 2 days ago
52%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
40%
Aroon
ODDS (%)
Bullish Trend 2 days ago
72%
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ELBM0.620.02
+2.83%
Electra Battery Materials Corp
BLDP3.680.09
+2.51%
Ballard Power Systems
IPAR134.26-1.23
-0.91%
Inter Parfums
CMPX1.97-0.02
-1.01%
Compass Therapeutics
HMC33.64-1.20
-3.44%
Honda Motor Co Ltd

LLY and

Correlation & Price change

A.I.dvisor indicates that over the last year, LLY has been loosely correlated with BIIB. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if LLY jumps, then BIIB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LLY
1D Price
Change %
LLY100%
-1.34%
BIIB - LLY
50%
Loosely correlated
-0.30%
NVS - LLY
42%
Loosely correlated
-0.46%
MRK - LLY
42%
Loosely correlated
-1.29%
AMGN - LLY
40%
Loosely correlated
-0.76%
GILD - LLY
39%
Loosely correlated
-0.62%
More